Research ExplorerPublicationsPLTP activity is a risk factor for subsequent cardiovascular...

PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study

Standard

PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. / Schlitt, Axel; Blankenberg, Stefan; Bickel, Christoph; Lackner, Karl J; Heine, Gunnar H; Buerke, Michael; Werdan, Karl; Maegdefessel, Lars; Raaz, Uwe; Rupprecht, Hans J; Munzel, Thomas; Jiang, Xian-Cheng.

In: J LIPID RES, Vol. 50, No. 4, 04.2009, p. 723-729.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schlitt, A, Blankenberg, S, Bickel, C, Lackner, KJ, Heine, GH, Buerke, M, Werdan, K, Maegdefessel, L, Raaz, U, Rupprecht, HJ, Munzel, T & Jiang, X-C 2009, 'PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study', J LIPID RES, vol. 50, no. 4, pp. 723-729. https://doi.org/10.1194/jlr.M800414-JLR200

APA

Schlitt, A., Blankenberg, S., Bickel, C., Lackner, K. J., Heine, G. H., Buerke, M., Werdan, K., Maegdefessel, L., Raaz, U., Rupprecht, H. J., Munzel, T., & Jiang, X-C. (2009). PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J LIPID RES, 50(4), 723-729. https://doi.org/10.1194/jlr.M800414-JLR200

Vancouver

Schlitt A, Blankenberg S, Bickel C, Lackner KJ, Heine GH, Buerke M et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study. J LIPID RES. 2009 Apr;50(4):723-729. https://doi.org/10.1194/jlr.M800414-JLR200

Bibtex

@article{43d44bb865874f34adff71e1567c575d,
title = "PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study",
abstract = "Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 patients who were on statins at baseline. In Kaplan-Meyer analyses serum PLTP activity was not associated with the combined endpoint in all patients. However, in the subgroup of patients receiving statins at baseline, PLTP was shown to be a significant predictor of cardiovascular outcome (P = 0.019), and this also remained stable in univariate (P = 0.027) and multivariate cox regression analyses (P = 0.041) including potential confounders (classical risk factors, HDL cholesterol (HDL-C), and others). We showed in our study that, under statin treatment, high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients.",
keywords = "Aged, Atherosclerosis/blood, Case-Control Studies, Coronary Artery Disease/blood, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Kaplan-Meier Estimate, Male, Middle Aged, Myocardial Infarction/blood, Phospholipid Transfer Proteins/blood, Prognosis, Risk Factors",
author = "Axel Schlitt and Stefan Blankenberg and Christoph Bickel and Lackner, {Karl J} and Heine, {Gunnar H} and Michael Buerke and Karl Werdan and Lars Maegdefessel and Uwe Raaz and Rupprecht, {Hans J} and Thomas Munzel and Xian-Cheng Jiang",
year = "2009",
month = apr,
doi = "10.1194/jlr.M800414-JLR200",
language = "English",
volume = "50",
pages = "723--729",
journal = "J LIPID RES",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene study

AU - Schlitt, Axel

AU - Blankenberg, Stefan

AU - Bickel, Christoph

AU - Lackner, Karl J

AU - Heine, Gunnar H

AU - Buerke, Michael

AU - Werdan, Karl

AU - Maegdefessel, Lars

AU - Raaz, Uwe

AU - Rupprecht, Hans J

AU - Munzel, Thomas

AU - Jiang, Xian-Cheng

PY - 2009/4

Y1 - 2009/4

N2 - Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 patients who were on statins at baseline. In Kaplan-Meyer analyses serum PLTP activity was not associated with the combined endpoint in all patients. However, in the subgroup of patients receiving statins at baseline, PLTP was shown to be a significant predictor of cardiovascular outcome (P = 0.019), and this also remained stable in univariate (P = 0.027) and multivariate cox regression analyses (P = 0.041) including potential confounders (classical risk factors, HDL cholesterol (HDL-C), and others). We showed in our study that, under statin treatment, high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients.

AB - Phospholipid transferprotein (PLTP) mediates both net transfer and exchange of phospholipids between different lipoproteins. Although many studies have investigated the role of PLTP in atherogenesis, the role of PLTP in atherosclerotic diseases is unclear. We investigated the association of serum PLTP activity with the incidence of a combined endpoint (myocardial infarction and cardiovascular death) and its relation to other markers of atherosclerosis in 1,085 patients with angiographically documented coronary artery disease (CAD). In the median follow-up of 5.1 years, 156 patients had suffered from the combined endpoint of myocardial infarction or cardiovascular death including 47 of 395 patients who were on statins at baseline. In Kaplan-Meyer analyses serum PLTP activity was not associated with the combined endpoint in all patients. However, in the subgroup of patients receiving statins at baseline, PLTP was shown to be a significant predictor of cardiovascular outcome (P = 0.019), and this also remained stable in univariate (P = 0.027) and multivariate cox regression analyses (P = 0.041) including potential confounders (classical risk factors, HDL cholesterol (HDL-C), and others). We showed in our study that, under statin treatment, high plasma PLTP activity was related to fatal and nonfatal cardiovascular events in CAD patients.

KW - Aged

KW - Atherosclerosis/blood

KW - Case-Control Studies

KW - Coronary Artery Disease/blood

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Myocardial Infarction/blood

KW - Phospholipid Transfer Proteins/blood

KW - Prognosis

KW - Risk Factors

U2 - 10.1194/jlr.M800414-JLR200

DO - 10.1194/jlr.M800414-JLR200

M3 - SCORING: Journal article

C2 - 19001358

VL - 50

SP - 723

EP - 729

JO - J LIPID RES

JF - J LIPID RES

SN - 0022-2275

IS - 4

ER -